Gilead Sciences Inc
(GILD)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 8,730,522 | 6,404,153 | 2,113,000 | 2,010,736 | 2,202,176 |
| Marketable Securities | 68,546 | 64,877 | 19,000 | 79,758 | 85,194 |
| Receivables | 3,436,711 | 3,236,195 | 2,182,000 | 1,971,926 | 1,895,913 |
| Inventories | 2,068,753 | 2,140,228 | 1,697,000 | 1,946,048 | 1,935,147 |
| Income taxes - deferred | 386,580 | 348,942 | 331,000 | 239,287 | 224,429 |
| Other current assets | 199,361 | 201,012 | 91,000 | 109,195 | 176,355 |
| TOTAL | $15,499,340 | $12,970,630 | $6,997,000 | $6,968,061 | $7,072,529 |
| Non-Current Assets | |||||
| PPE Net | 1,380,776 | 1,303,029 | 1,166,000 | 1,133,032 | 1,135,993 |
| Investments And Advances | 782,315 | 389,871 | 439,000 | 665,063 | 688,428 |
| Intangibles | 12,679,881 | 12,879,391 | 13,069,000 | 13,222,617 | 13,244,157 |
| Other Non-Current Assets | 863,858 | 534,769 | 908,000 | 479,658 | 483,262 |
| TOTAL | $15,706,830 | $15,107,060 | $15,582,000 | $15,500,370 | $15,551,840 |
| Total Assets | $31,206,160 | $28,077,690 | $22,579,000 | $22,468,430 | $22,624,370 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 1,572,079 | 1,871,811 | 2,697,000 | 1,457,379 | 1,488,225 |
| Accounts payable and accrued liabilities | 1,162,307 | 1,234,507 | 1,256,000 | 1,350,402 | 1,390,641 |
| Accrued Expenses | 1,826,648 | 1,320,892 | 1,261,000 | 1,132,666 | 1,076,780 |
| TOTAL | $6,227,997 | $5,914,776 | $6,407,000 | $4,895,124 | $4,937,138 |
| Non-Current Liabilities | |||||
| Long Term Debt | 8,106,732 | 8,106,977 | 3,939,000 | 6,117,184 | 6,074,179 |
| Deferred Revenues | 126,284 | 111,792 | 111,000 | 127,278 | 112,119 |
| Other Non-Current Liabilities | 380,113 | 275,785 | 410,147 | 122,979 | 127,577 |
| TOTAL | $8,548,825 | $8,460,722 | $4,427,000 | $6,380,831 | $6,343,852 |
| Total Liabilities | $14,776,820 | $14,375,500 | $10,834,000 | $11,275,960 | $11,280,990 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,511,670 | 1,535,682 | 1,538,253 | 1,533,349 | 1,530,626 |
| Common Shares | 1,526 | 1,538 | 2,000 | 763 | 765 |
| Retained earnings | 10,199,580 | 7,734,979 | 6,106,000 | 5,735,335 | 5,065,839 |
| Other shareholders' equity | 297,247 | 219,099 | 251,000 | 266,790 | 281,751 |
| TOTAL | $16,429,340 | $13,702,190 | $11,745,000 | $11,192,470 | $11,343,380 |
| Total Liabilities And Equity | $31,206,160 | $28,077,690 | $22,579,000 | $22,468,430 | $22,624,370 |